Vimarsana
Biggest News Aggregation in the World

Page 9 - Dose Escalation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dose Escalation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dose Escalation Today - Breaking & Trending Today

CNN The Lead With Jake Tapper August 19, 2021 20:36:00 - Vimarsana News

CNN The Lead With Jake Tapper August 19, 2021 20:36:00

And 300 million in the beginning of next year. weave already given over 115 million dozes to 60 countries and $4 billion. we do believe there is an issue. we want to get dozes to the rest of the world, but we can do both things. we can protect our citizens and play the major role in getting vaccines to the rest of the world. >> let's talk about kids and schools. for children under 12, surgeon general murthy says the fda will move fast to approve the vaccines when they approve the data. when should we expect a vaccine announcement for children under 12? >> i have to be honest with you, i don't ...

Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual 26th Annual Congress of the European Hematology Association. Phase I/II Data for SEL24 (MEN1703) presented by development partner Menarini - Vimarsana News

Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual 26th Annual Congress of the European Hematology Association. Phase I/II Data for SEL24 (MEN1703) presented by development partner Menarini

Ryvu Therapeutics (WSE:RVU) today announced the online publication of two posters and an oral presentation demonstrating clinical and pre-clinical activity of its selective CDK8/19 inhibitor RVU120 (previously SEL120) and the dual PIM/FLT3 inhibitor SEL24 (MEN1703), in-licensed by Menarini Group from Ryvu Therapeutics, at the Annual European Hematology Association (EHA) 2021 Virtual Congress.

Source: yahoo.com
Daiichi Sankyo Company, Limited: Patritumab Deruxtecan Data at ASCO Demonstrates Tumor Response Across Multiple Resistance Mechanisms in Patients with Advanced EGFR-Mutated NSCLC - Vimarsana News

Daiichi Sankyo Company, Limited: Patritumab Deruxtecan Data at ASCO Demonstrates Tumor Response Across Multiple Resistance Mechanisms in Patients with Advanced EGFR-Mutated NSCLC

Oral presentation highlighting extended follow-up data from phase 1 study in patients with locally advanced or metastatic TKI-resistant, EGFR-mutated NSCLC shows promising clinical activity Data

UPDATE -- Vincerx Pharma Presents Clinical Data on VIP152, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at ASCO 2021 - Vimarsana News

UPDATE -- Vincerx Pharma Presents Clinical Data on VIP152, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at ASCO 2021

VIP152 shows favorable safety, on-target pharmacodynamics and signs of durable metabolic complete responses in monotherapy setting Phase 1b study in MYC-Driven relapsed/refractory aggressive lymphomas and advanced solid tumors ongoing PALO ALTO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced the presentation of safe

Source: yahoo.com
Harpoon Therapeutics Provides Progress Update for TriTAC® Clinical Programs and ProTriTAC™ Platform - Vimarsana News

Harpoon Therapeutics Provides Progress Update for TriTAC® Clinical Programs and ProTriTAC™ Platform

Three TriTAC clinical programs (HPN424, HPN536 and HPN328) have shown tumor size reductions or stable disease, and meaningful treatment durationAll four clinical programs demonstrate half-life extension, target engagement and T cell activationCytokine release syndrome observed and manageable, with low incidence of severe CRSManagement to host webcast and conference call to review the interim data presented at ASCO and provide a pipeline update today at 4 p.m. ET /1 p.m. PT SOUTH SAN FRANCISCO, C

Source: yahoo.com